Full-Time

Equipment Associate I

Posted on 2/19/2025

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Biotechnology
Healthcare

Compensation Overview

$21.51 - $30Hourly

Entry, Junior

Company Historically Provides H1B Sponsorship

San Carlos, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Inventory Management

You match the following Natera's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • AA/AS OR BS/BA in biomedical engineering or related fields.
  • Industry-related experience, especially in supporting lab equipment, preferred.
Responsibilities
  • Coordinate and/or perform instrument installations and qualifications per equipment protocols.
  • Diagnose and troubleshoot any system concerns to minimize downtime.
  • Work with Quality Assurance to determine qualification (IQ/OQ/PQ), calibration and preventive maintenance (PM) requirements so as to comply with regulations.
  • Communicate with vendors to generate price quotes and schedule PMs, calibrations, instrument repairs, and other services.
  • Maintain a program for PM, routine maintenance and calibration to ensure all lab equipment remains fit for purpose.
  • Prepare equipment SOPs. Support and comply with the company’s Quality Management System policies and procedures.
  • Track all service activities utilizing system(s) developed in accordance with service procedures and laboratory policies.
  • Ensure all service documentation is complete, timely, and accurate following Good Documentation Practices (GDP).
  • Perform inventory checks for R&D lab spaces and replenish supplies as needed.
  • Order supplies from internal and external sources as needed.
  • Perform regular safety checks and assist with Safety audits as well as perform any corrective actions needed that may result from safety audits/checks.
  • Communicate with various members of the R&D team to schedule instrument downtime for maintenance or repairs, inform them of supply deliveries, update them about the status of requests etc.
Desired Qualifications
  • Familiar with IQ/OQ/PQ of instruments
  • Experience working in BSLI and BSLII laboratories as well as familiarity with Biosafety requirements and guidelines as established by applicable regulatory bodies such as OSHA and CDC.
  • Familiar with DNA Isolation and Purification, PCR, Cell Culture, Next Generation Sequencing, etc.
  • Familiar with LIMS.
  • Experience in automation and/or operating high-throughput instruments

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and organ health assessment. Their products include the Signatera test for cancer patients and the Panorama NIPT for prenatal screening, with a strong emphasis on personalized genetic counseling. Natera stands out by providing specialized testing services directly to healthcare providers and patients, ensuring early detection of health issues. The company's goal is to improve patient care through advanced genetic testing solutions.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • Growing personalized medicine trend enhances need for Natera's customized genetic tests.
  • Expansion of telehealth services aligns with Natera's remote genetic counseling offerings.

What critics are saying

  • Allegations of deceptive practices could harm Natera's reputation and lead to legal issues.
  • New Prospera Heart features may face adoption challenges without independent validation.
  • Ongoing legal investigations could result in financial penalties affecting Natera's stability.

What makes Natera unique

  • Natera's Signatera test offers significant lead time in detecting cancer recurrence.
  • Prospera Heart test integrates Donor Quantity Score for enhanced transplant rejection detection.
  • Panorama NIPT uniquely determines fetal RhD status, aiding in prenatal care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

10%
BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

Yahoo Finance
Jun 17th, 2024
Natera Launches Differentiated New Feature For Prospera(Tm) Heart Test, Enhancing Detection Of Rejection For Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection